Investor Alert: Pomerantz Law Firm Investigates Potential Securities Fraud at Beam Therapeutics Inc.
Pomerantz LLP is investigating potential securities fraud or other unlawful business practices by Beam Therapeutics Inc. (NASDAQ: BEAM) and certain of its officers or directors on behalf of investors. The investigation follows a September 8, 2026 press release from the company announcing updated clinical data for its gene therapy candidate, BEAM-302, in treating alpha-1 antitrypsin deficiency. The announcement revealed that while treatment was well-tolerated overall with an acceptable safety profile, there were transient and predominantly Grade 1 elevations of liver enzymes ALT and AST observed. This news led to a significant drop in Beam's stock price by $2.83 per share (9.54%) on the same day. Pomerantz LLP is one of the leading firms specializing in corporate, securities, and antitrust class litigation. The firm has recovered multimillion-dollar damages for victims of financial misconduct over its 85-year history.
Tickers: $BEAM